A5102945842- Renal cell carcinoma treatment
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Cardiac tumors and thrombi
- Prostate Cancer Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Advanced Breast Cancer Therapies
- Radiopharmaceutical Chemistry and Applications
- Tuberous Sclerosis Complex Research
- Genetic and Kidney Cyst Diseases
- Urinary and Genital Oncology Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Peripheral Neuropathies and Disorders
- Multiple and Secondary Primary Cancers
- Multiple Sclerosis Research Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Mechanisms and Therapy
Institute of Oncology Research
2025
Ente Ospedaliero Cantonale
2023-2024
Barmherzige Schwestern Krankenhaus Wien
2020
AGO Austria
2018-2019
Comprehensive Cancer Center Vienna
2008-2016
Medical University of Vienna
2009-2016
European Association of Nuclear Medicine
2007
Vienna General Hospital
2006
Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported approximately 10% of the patients. Detailed cardiovascular monitoring during TKI treatment may reveal early signs myocardial damage.In this observational, single-center study, all patients intended for were analyzed coronary artery disease (CAD) risk factors, history or evidence CAD, hypertension, rhythm disturbances,...
Abstract BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important antitumor activity in metastatic renal cell carcinoma (mRCC). Hypothyroidism constitutes a commonly reported side effect of both drugs, particularly sunitinib. The objective this analysis was to investigate whether the occurrence hypothyroidism during treatment with sunitinib affects outcome patients mRCC. METHODS: Eighty‐seven consecutive mRCC who were receive or included prospective analysis....
Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated or on several different treatment approaches. The aim of this analysis was to define prognostic treated uniformly a low-dose outpatient cytokine combination. relationship between patient-, tumour-, treatment-related analysed 99 MRCC. These features were first examined univariate analyses, then stepwise modelling approach based Cox regression used form multivariate...
Locally advanced or metastatic adenocarcinoma of the pancreas remains - despite implementation new chemotherapy protocols a disease with short overall survival (OS).Eighty-three patients were treated locally either FOLFIRINOX nab-Paclitxel and Gemcitabine (nabPGem) as first- second line therapy. We analysed outcome for OS progression-free (PFS) in terms treatment regimen sequence.The majority presented good performance status (PS) median age 68 years. Fourty-two received first-line therapy,...
243 Background: Alterations in AVPC-TSG (TP53, RB1, PTEN) are related with androgen insensitivity and aggressive disease. However, their role mHSPC prognosis treatment guidance is unclear. This retrospective study assesses the value of alterations refining predicting ARPI benefit mHSPC. Methods: We included 158 patients available genomic tumor sequencing analysis undergoing between 2013 2023. compared AVPC-TSGalt tumors (defined by ≥1 TP53 gene, RB1 or PTEN/PI3K/AKT pathway genes) to those...
// Magdalena Lukamowicz-Rajska 1 , Christiane Mittmann Michael Prummer 2 Qing Zhong Jens Bedke 3 Jörg Hennenlotter Arnulf Stenzl Axel Mischo 4 Svenja Bihr Manuela Schmidinger 5 Ursula Vogl Iris Blume 6 Christoph Karlo Peter Schraml and Holger Moch Institute of Surgical Pathology, University Hospital Zürich, Zurich, Switzerland NEXUS Personalized Health Technologies, ETH Department Urology, Tübingen, Germany Oncology Department, Internal Medicine I, Division & Comprehensive Cancer Center...
In the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a significantly shorter survival than without. Targeted agents (TA) have improved outcome metastatic (mRCC) however, their impact on BM is less clear. The aim this analysis was to compare and without in targeted agents.Data 114 consecutive who access agent were analyzed for response rates (ORR), progression free (PFS) overall (OS). All diagnosed underwent local, BM-specific treatment before initiation...
Background: Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from treated ramucirumab and paclitaxel or FOLFIRI after failure of at least one platinum- 5-FU-containing chemotherapy (CHT) regimen. Methods: In this retrospective two-center study, 56 gastric cancer (47%) adenocarcinoma the GEJ (53%) were (n=38) as second-line (75%) beyond (25%)...
Treatment decisions in routine clinical practice are based on reports of trials, which represent highly selected populations. Limited studies reported real-world evidences representing practices patients with renal-cell carcinoma (RCC) Europe. The aim this retrospective, noninterventional chart review was to collect data the treatment landscape for advanced/metastatic RCC a broader patient population Austria. Patients receiving systemic between June 2010 and 2016 across 12 centers Austria...
Background. First line treatment with temsirolimus is considered standard of care in poor risk patients metastatic renal cell carcinoma. The role pretreated any profile unclear. aim this retrospective analysis was to investigate the impact who had progressed on various lines. Material and methods. From April 2007 July 2009, all receptor-tyrosine kinase-inhibitors, VEGF-antibodies other agents were treated (25 mg weekly). Physical examination, white blood count chemistry obtained weekly tumor...
This study assessed the cost-effectiveness of nivolumab plus ipilimumab versus both sunitinib and pazopanib for treatment first-line unresectable advanced renal cell carcinoma (aRCC) from a healthcare system perspective in Switzerland.A three-state partitioned survival model, consisting progression-free, progressed disease, death, was constructed. Efficacy estimates were based on data CheckMate 214 trial (NCT02231749) with minimum follow-up 42 months. Two Swiss oncologists consulted to...
5110 Background: Tyrosine-kinase inhibitors (TKI) of the VEGF and PDGF-receptor have significant clinical activity in patients with renal cell carcinoma (RCC). These agents target VHL-hypoxia-inducible gene pathway lead to inhibition hypoxia- inducible factor (HIF)-induced products. Physiologically, HIF-1 related products are important mediators myocardial response ischemia, remodeling, peri-infarct vascularisation vascular permeability. The aim this prospective observational study was...
16125 Background: First-line treatment with the mTOR inhibitor Temsirolimus was shown to improve progression free survival and in patients metastatic renal cell carcinoma poor MSKCC risk profile. The role of being heavily pretreated cytokines targeted agents is unclear. aim this analysis investigate impact who had progressed under various types therapies. Methods: From April November 2007, all were offered at a dose 25mg. White blood count chemistry obtained weekly, detailed physical...
Neurologic complications after allogeneic hematopoietic stem cell transplantation (HSCT) are rare but poorly understood. We present a case report of 57-year-old-male patient who was diagnosed in 2009 with acute myeloid leukemia (AML). He received two standard induction chemotherapies, as well following consolidation. Six months later, an HSCT performed. Shortly the developed progressive polyneuropathy lower legs and hypoesthesia. Five later severe dementia followed. All images brain spine...
e15535 Background: Axitinib is a highly selective inhibitor of VEGFR-1, 2 and 3 has recently been approved for second-line treatment metastatic renal cell cancer (mRCC). We present data 43 patients treated with axitinib in beyond. Methods: Medical records all who were between July 2009 December 2012 retrospectively reviewed. was prescribed at dose 5 mg bid escalated to 7 or 10 the absence hypertension other dose-limiting toxicities. Objective response rate (ORR) assessed by RECIST....
e15090 Background: Treatment with pazopanib was shown to improve objective response rates (ORR) and progression free survival (PFS) when compared placebo in treatment-naïve or cytokine-pretreated patients mRCC. We assessed the efficacy safety of an unselected group mRCC-patients at Medical University Vienna. Methods: records all who were treated between June 2010 January 2012 retrospectively reviewed. Pazopanib prescribed a dose 800 mg daily. given until disease unacceptable toxicity. ORR by...
e12522 Background: We evaluate the efficacy of bevacizumab in combination with liposomal doxorubicin patients recurrent high grade gliomas (HGG). Methods: Twenty-one (seven women and 14 men, median age 48 years, range 27 to 66 years) were assigned receive 10 mg/kg 20 mg/m2 once every 2 weeks (Bev+D). Among them, six presented III glioma, fifteen relapsed glioblastoma multiforme had been treated at least one up three chemotherapy regimes previously. looked 6-month progression-free survival...
e15585 Background: Sequential treatment with sunitinib and axitinib was shown to improve survival in mRCC up 33.7 months. Modifying the schedule of (to 2 weeks on-1 week off stead 4 on-2 off) appears tolerability without impairing progression-free (PFS). The aim this analysis investigate outcome an upfront 2/1-schedule real world patients. As RECIST-defined PFS may not always reflect duration clinical benefit daily practice, investigator’s perceived occurrence resistance, defined as time...